PHARNEXT overview

PARIS, France, March 11, 2024, 04:30 pm CET – Pharnext SA ( FR001400N1P4 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, provides a comprehensive overview of operational, strategic and financial issues following recent announcements. UPDATE ON CLINICAL TRIAL RESULTS As indicated in press releases on December 11, 2023 [1] , December 19, 2023 [2] and February 28,...

PARIS, France, February 28, 2024, 08:30 am CET – Pharnext SA ( FR001400N1P4 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, provides an update on the ongoing analysis of data from pivotal Phase III study (PREMIER trial) of PXT3003, its drug candidate in Charcot-Marie-Tooth disease type 1A (CMT1A). As a reminder, on December 11, 2023, Pharnext announced that, on the...

PARIS, France, January 17, 2024, 08:30 am CET – Pharnext SA (FR001400JXB0 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the implementation of a drastic cost-cutting plan designed to provide the Company with the financial visibility it needs to continue the development of PXT3003, its drug candidate for Charcot-Marie-Tooth disease type 1A (CMT1A),...

PARIS, France, January 17, 2024, 08:30 am CET – Pharnext SA (FR001400JXB0 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the implementation of a drastic cost-cutting plan and the confirmed support of its financial partners to provide the Company with the financial visibility it needs to continue the development of PXT3003, its drug candidate for...

PARIS, France, December 19, 2023, 08:30 am CET – Pharnext SA (FR001400JXB0 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today unveils its intentions after continuing the analysis of pivotal Phase III clinical results (PREMIER trial) for PXT3003, its drug candidate in Charcot-Marie-Tooth disease type 1A (CMT1A), a rare debilitating peripheral neuropathy....

PARIS, France, December 11, 2023, 08:30 am CET – Pharnext SA (FR001400JXB0 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces topline results of its pivotal Phase III clinical study (PREMIER trial) of PXT3003 [1] , its drug candidate in Charcot-Marie-Tooth disease type 1A (CMT1A), a rare debilitating peripheral neuropathy. One of the main challenges in...

PARIS, France, December 4, 2023, 08:30 am CET – Pharnext SA ( FR001400JXB0 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the successful completion of database lock for its pivotal Phase III clinical study (PREMIER trial) of PXT3003 [1] , its drug candidate in Charcot-Marie-Tooth disease type 1A (CMT1A), a rare debilitating peripheral neuropathy....

PARIS, France, November 27, 2023, 08:30 am CET – Pharnext SA ( FR001400JXB0 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today unveils a new calendar for negotiations to sign an agreement valuing PXT3003 [1] , its drug candidate in Charcot-Marie-Tooth disease type 1A (CMT1A), a rare debilitating peripheral neuropathy. As announced [2] , the Company received 3...